Controlling Pharmaceutical Risks

Controlling Pharmaceutical Risks analyses changes in drug testing since the late 1990s, specifically geneticization of carcinogenic risk assessment and regulation of pharmaceuticals, involving issues fundamental to bio-science, medical treatment and patients¿ health, such as what knowledge is judged necessary to determine carcinogenic risk to humans, and how that judgement transpired.